Evommune (EVMN) Non-Current Assets (2024 - 2026)

Evommune (EVMN) posted quarterly Non-Current Assets of $106.6 million for Q1 2026, up 49.16% quarter-over-quarter from $71.5 million in Q4 2025.

Evommune (EVMN) Non-Current Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Non-Current Assets for 3 consecutive years, with $106.6 million the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Assets changed N/A year-over-year to $106.6 million; the TTM figure through Mar 2026 stood at $182.7 million (changed N/A YoY), while the FY2025 annual figure was $71.5 million, up 3357.57% from the prior year.
Non-Current Assets advanced to $106.6 million in Q1 2026 per EVMN's latest filing, from $71.5 million in the prior quarter.
Across five years, Non-Current Assets topped out at $106.6 million in Q1 2026 and bottomed at $2.1 million in Q4 2024.
Historically, Non-Current Assets has averaged $45.7 million across 3 years, with a median of $37.0 million in 2025.
On a YoY basis, Non-Current Assets climbed as much as 3357.57% in 2025 and fell as far as 3357.57% in 2025.
Evommune's Non-Current Assets stood at $2.1 million in 2024, then surged by 3357.57% to $71.5 million in 2025, then soared by 49.16% to $106.6 million in 2026.
Business Quant data shows EVMN's Non-Current Assets at $106.6 million in Q1 2026, $71.5 million in Q4 2025, and $2.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.96 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	294.93 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.96 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3.76 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	18.06 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	938.60 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	468.65 Mn
10	Evommune	531.53 Mn	330.73 Mn	-	97.70 Mn

Download Data